Kirk Randal J Maintains 46.7% Stake in Intrexon Corporation (NYSE:XON)

Kirk Randal J

revealed that they own 46.7% of Intrexon Corporation (NYSE:XON) in a Form 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Wednesday, July 26th. The investor owns 56,223,681 shares of the stock valued at about $1,104,795,332. The reporting parties listed on the disclosure included Randal J Kirk, Rj Kirk Declaration Of Trust, Irs Identification No: 541923091, Third Security Capital Partners V, LLC, Irs Identification No: 271471440 and Irs Identification No: 452595931. The disclosure is available through Edgar at this hyperlink.

Kirk Randal J

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(https://whalewisdom.com
56,223,681
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Other hedge funds and other institutional investors have also modified their holdings of the company. John G Ullman & Associates Inc. acquired a new position in shares of Intrexon Corporation during the second quarter valued at $212,000. CWM LLC raised its position in Intrexon Corporation by 1.7% in the second quarter. CWM LLC now owns 36,143 shares of the biotechnology company’s stock valued at $871,000 after buying an additional 597 shares in the last quarter. Sanders Morris Harris LLC raised its position in Intrexon Corporation by 1.5% in the second quarter. Sanders Morris Harris LLC now owns 95,050 shares of the biotechnology company’s stock valued at $2,290,000 after buying an additional 1,360 shares in the last quarter. Creative Planning raised its position in Intrexon Corporation by 13.9% in the second quarter. Creative Planning now owns 25,408 shares of the biotechnology company’s stock valued at $612,000 after buying an additional 3,100 shares in the last quarter. Finally, Cullinan Associates Inc. purchased a new position in Intrexon Corporation during the second quarter valued at approximately $201,000. Institutional investors own 84.38% of the company’s stock.

Intrexon Corporation (XON) traded up 5.31% during mid-day trading on Friday, hitting $19.65. The stock had a trading volume of 2,111,631 shares. The company has a 50 day moving average price of $22.92 and a 200 day moving average price of $21.94. Intrexon Corporation has a one year low of $17.70 and a one year high of $32.90. The stock’s market cap is $2.37 billion.

Intrexon Corporation (NYSE:XON) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.05. The firm had revenue of $54.40 million for the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.04%. Intrexon Corporation’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.42) earnings per share. On average, equities analysts anticipate that Intrexon Corporation will post ($0.87) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/14/kirk-randal-j-maintains-46-7-stake-in-intrexon-corporation-nysexon-updated-updated.html.

Several research firms have recently commented on XON. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Northland Securities set a $30.00 price target on Intrexon Corporation and gave the stock a “buy” rating in a research report on Monday, August 7th. Finally, Zacks Investment Research upgraded Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Tuesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Intrexon Corporation has a consensus rating of “Hold” and an average target price of $40.50.

In other news, Director Dean J. Mitchell purchased 5,000 shares of the company’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $18.33 per share, for a total transaction of $91,650.00. Following the completion of the purchase, the director now owns 18,103 shares of the company’s stock, valued at $331,827.99. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 7,094 shares of company stock worth $129,593 in the last 90 days. 55.10% of the stock is owned by company insiders.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Institutional Ownership by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply